Lexaria Bioscience
LEXX
25 hedge funds and large institutions have $3.23M invested in Lexaria Bioscience in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
116% more capital invested
Capital invested by funds: $1.49M → $3.23M (+$1.73M)
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
25% more funds holding
Funds holding: 20 → 25 (+5)
4.62% less ownership
Funds ownership: 11.63% → 7.01% (-4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$117K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$101K |
| 3 |
State Street
Boston,
Massachusetts
|
+$100K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.2K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$63.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$659K |
| 2 |
CAC
Cowen and Company
New York
|
-$320K |
| 3 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$75K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$34.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.92K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
26
Cowen and Company
New York
| – | -$320K | -256,327 | Closed |
|
|
CCM
27
Connective Capital Management
Palo Alto,
California
| – | -$75K | -60,000 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$5.67K | -4,532 | Closed |
|
29
JP Morgan Chase
New York
| – | -$1.27K | -1,019 | Closed |
|
|
SIS
30
Sound Income Strategies
Ft Lauderdale,
Florida
| – | -$28 | -22 | Closed |
|
LEXX Hedge Fund Activity: Q1 2024 in Review
25 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2024, worth a combined $3.23M — up 116% from $1.49M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LEXX positions and 5 closed out — a net gain of 5 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $117K. The largest seller was Invenomic Capital Management, cutting an estimated $659K.
- 25 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2024, up from 20 in Q4 2023.
- Funds reported $3.23M of Lexaria Bioscience stock for Q1 2024, up 116% quarter-over-quarter.
- 10 funds opened new Lexaria Bioscience positions in Q1 2024 and 5 closed out, a net change of +5 holders.
- The largest Lexaria Bioscience buyer in Q1 2024 was Geode Capital Management, an estimated $117K added.
- The largest Lexaria Bioscience seller in Q1 2024 was Invenomic Capital Management, an estimated $659K sold.
Based on aggregated 13F filings for Q1 2024.